Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.47 |
| ▸ | NPY1R | P25929 | 10/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.47 |
| ▸ | NPY2R | P49146 | 6/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633542 | 0.97 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RACE | |
| SCHEMBL29534002 | 0.97 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RACE | |
| SCHEMBL29534033 | 0.93 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RACE | |
| SCHEMBL29565556 | 0.91 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29355526 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7861255 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7861254 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29564351 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL6073057 | 0.88 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL6073065 | 0.88 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | PAUL SCHERRER INSTITUT (CH) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NPY4R 773/4885NPY1R 1206/4885NPY5R 1749/4885 |
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | TGM3, TGM2, GLUL | NPY4R 2474/4885NPY1R 2136/4885NPY5R 2019/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | NPY4R 773/4885NPY1R 1206/4885NPY5R 1749/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NPY4R 773/4885NPY1R 1206/4885NPY5R 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.